Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

T3D 959

Next Previous
Drug Profile

T3D 959

Alternative Names: DB-959; DB-959Na; T3D-959

Latest Information Update: 23 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer DARA BioSciences; T3D Therapeutics
  • Class Acetates; Antidementias; Antihyperglycaemics; Antihyperlipidaemics; Hepatoprotectants; Indenes; Insulin sensitisers; Oxazoles; Small molecules; Sodium compounds
  • Mechanism of Action Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • No development reported Huntington's disease; Non-alcoholic fatty liver disease
  • Discontinued Dyslipidaemias; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Most Recent Events

  • 09 May 2025 T3D Therapeutics plans a phase II/III trial for Alzheimer's Disease in USA (PO, Capsule) (NCT06964230)
  • 28 Jul 2024 Updated efficacy data from the phase II PIONEER trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2024 (AAIC-2024)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Huntington's-disease in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top